Hormonal adjuvants for the treatment of renal anaemia
Most patients find that once they stay on a consistent dose for several months, the profound fatigue is replaced by a more stable, sustainable energy level
Primary antibodies [Rabbit anti-GLP1R (#PA5-97789, Invitrogen
In some embodiments, the formulations described herein have a pH and/or practical osmolarity as described herein, and have a concentration of active pharmaceutical ingredient from about 0.0001% to about 60%, from about 0.001% to about 40%, from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.01% to about 7.5%, from about 0.01% to about 6%, from about 0.01 to about 5%, from about 0.1 to about 10%, or from about 0.1 to about 6% of the active ingredient by weight of the formulation